Clinical and Experimental Dermatology · 2001 · 133 citations · 11 references
MedicineDermatologyPharmacologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal TherapyDrug-induced Skin ReactionsFungal InfectionsAspergillosis TherapyDiscoid Lupus Erythematosus AlopeciaFungal Skin DiseasesInvasive Aspergillosis ManagementInvasive Aspergillosis TreatmentItraconazole TherapyNew Antifungal AgentsSkin Erythema
Voriconazole is a new azole antifungal drug with activity against a wide range of systemic fungal pathogens, including Aspergillus spp. Five patients with chronic invasive aspergillosis were treated for 12-58 weeks with voriconazole, 200 mg twice daily and developed facial erythema and cheilitis. One who received 58 weeks of therapy also developed discoid lupus erythematosus-like lesions on both sides of her neck. Both erythema and cheilitis resolved after discontinuation of voriconazole. Serum retinoids were elevated in the three patients in whom they were measured. Voriconazole has the potential for retinoid-like side-effects and facial erythema.
11
Voriconazole: A New Triazole Antifungal
Janelle Sabo, Susan M. Abdel‐Rahman · Annals of Pharmacotherapy · 2000 · 173 citations